Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
VCEL logo VCEL
Upturn stock ratingUpturn stock rating
VCEL logo

Vericel Corp Ord (VCEL)

Upturn stock ratingUpturn stock rating
$35.77
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: VCEL (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

8 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $53.88

1 Year Target Price $53.88

Analysts Price Target For last 52 week
$53.88 Target price
52w Low $33.09
Current$35.77
52w High $63

Analysis of Past Performance

Type Stock
Historic Profit -38.73%
Avg. Invested days 30
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.80B USD
Price to earnings Ratio 255.5
1Y Target Price 53.88
Price to earnings Ratio 255.5
1Y Target Price 53.88
Volume (30-day avg) 8
Beta 1.27
52 Weeks Range 33.09 - 63.00
Updated Date 08/15/2025
52 Weeks Range 33.09 - 63.00
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) 0.14

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2025-07-31
When -
Estimate -0.03
Actual -0.01

Profitability

Profit Margin 2.85%
Operating Margin (TTM) -3.21%

Management Effectiveness

Return on Assets (TTM) 0.18%
Return on Equity (TTM) 2.59%

Valuation

Trailing PE 255.5
Forward PE 78.74
Enterprise Value 1787844532
Price to Sales(TTM) 7.25
Enterprise Value 1787844532
Price to Sales(TTM) 7.25
Enterprise Value to Revenue 7.18
Enterprise Value to EBITDA 110.44
Shares Outstanding 50460200
Shares Floating 49903124
Shares Outstanding 50460200
Shares Floating 49903124
Percent Insiders 1.06
Percent Institutions 111.05

ai summary icon Upturn AI SWOT

Vericel Corp Ord

stock logo

Company Overview

overview logo History and Background

Vericel Corporation was founded in 1989. It focuses on advanced cell therapies for sports medicine and severe burn care.

business area logo Core Business Areas

  • Sports Medicine: Vericel develops and commercializes autologous chondrocyte implantation (ACI) products for cartilage repair.
  • Severe Burn Care: Vericel offers a cell therapy for the treatment of severe burns.

leadership logo Leadership and Structure

The leadership team consists of the CEO, CFO, and other key executives. The organizational structure includes departments for R&D, manufacturing, commercial operations, and finance.

Top Products and Market Share

overview logo Key Offerings

  • MACI: MACI (autologous cultured chondrocytes on porcine collagen membrane) is used to repair cartilage defects in the knee. Vericel holds a significant market share within the ACI market. Competitors include surgical procedures like microfracture and other cartilage repair techniques. Estimated 80-85% market share within its niche.
  • Epicel: Epicel (cultured epidermal autografts) is a permanent skin replacement for patients with severe burns. Epicel has less market share with other skin graphs available. Competitors include Integra LifeSciences (IART) and Mallinckrodt (MNK). Estimated market share 10-15% within its niche.

Market Dynamics

industry overview logo Industry Overview

The cell therapy market is experiencing growth, driven by advances in regenerative medicine and increasing demand for minimally invasive treatments.

Positioning

Vericel is a leader in the ACI market with MACI and has a niche position in severe burn care with Epicel. Its competitive advantage lies in its proprietary cell therapy technologies and established commercial infrastructure.

Total Addressable Market (TAM)

The TAM for cell therapies in sports medicine and burn care is estimated to be several billion dollars. Vericel is well positioned to capture a portion of this TAM with its established products and ongoing research and development.

Upturn SWOT Analysis

Strengths

  • Established products with clinical data
  • Strong brand recognition in the ACI market
  • Proprietary cell therapy technologies
  • Experienced management team

Weaknesses

  • Limited product portfolio
  • High manufacturing costs
  • Reliance on a single manufacturing facility
  • Reimbursement challenges

Opportunities

  • Expansion of MACI to new indications
  • Development of new cell therapies for other conditions
  • Geographic expansion
  • Strategic partnerships

Threats

  • Competition from other cell therapy companies
  • Regulatory changes
  • Economic downturn
  • Product liability claims

Competitors and Market Share

competitor logo Key Competitors

  • IART
  • MNK

Competitive Landscape

Vericel has a strong position in the ACI market with MACI, but faces competition in the burn care market from companies like Integra LifeSciences and Mallinckrodt. Vericel's competitive advantage lies in its proprietary cell therapy technologies.

Major Acquisitions

None

  • Year: 0
  • Acquisition Price (USD millions): 0
  • Strategic Rationale: N/A

Growth Trajectory and Initiatives

Historical Growth: Historically Vericel has grown with strong growth in the cartilage market.

Future Projections: Analyst projections suggest continued growth for Vericel, driven by increased adoption of MACI and potential new product launches.

Recent Initiatives: Recent initiatives include expanding MACI's reach and pursuing partnerships.

Summary

Vericel is a specialized biotech firm focused on cell therapies. Their cartilage repair product, MACI, dominates its market, and Epicel addresses burn treatment, though with more competition. Growth prospects are promising, but manufacturing costs and reimbursement hurdles pose challenges. Vericel's focused approach positions it well within niche regenerative medicine segments but exposes it to portfolio risk.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Filings
  • Analyst Reports
  • Industry Publications

Disclaimers:

The information provided is for informational purposes only and should not be considered investment advice. Market share data are estimates and may not be precise.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Vericel Corp Ord

Exchange NASDAQ
Headquaters Cambridge, MA, United States
IPO Launch date 1997-02-04
CEO, President & Director Mr. Dominick C. Colangelo Esq.
Sector Healthcare
Industry Biotechnology
Full time employees 357
Full time employees 357

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.